Acadia Pharmaceuticals | ACAD - 应收帐款人



金融业
股票价格
USD
资产
USD 1.74B
现金及等价物
USD 956.47M
销售成本
USD 28.32M
流动资产
USD 1.22B
流动负债
USD 361.44M
债务
USD 50.79M
EBIT
USD 37.84M
EBITDA
USD -1.62M
员工
653
EPS每股收益
USD 0.18
股本和储备
USD 1.31B
销售毛利
USD 279.64M
债务利息支出
USD 0
利息收入
USD 8.06M
贷款资金
USD 0
市值
USD 4.81B
净收入
USD 31.5M
营业费用
USD 270.12M
营业利润
USD 37.84M
普通股股本
USD 171.09M
PE价格收益
11.33
税前利润
USD 46.47M
销售收入
USD 307.96M
销售和管理费用
USD 148.57M
股票
USD 108.67M
贸易债权人
USD 44.57M
应收帐款人
USD 166.33M


应收帐款人 更改 日
Acadia Pharmaceuticals USD 166.33M 17.95M 2026-06
ALKERMES USD 456.48M 48.85M 2026-06
Alnylam Pharmaceuticals USD 912.74M 28.78M 2026-06
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 1.06B 157.13M 2026-06
Bristol-Myers Squibb USD 13.83B 535M 2026-06
Cara Therapeutics USD 2.24M 2.26M 2025-03
Corcept Therapeutics USD 76.92M 37.85M 2026-06
Cytokinetics USD 6.83M 10.94M 2026-03
Eisai JPY 253.13B 26.12B 2026-06
Eli Lilly USD 23.48B 2.3B 2026-06
Incyte USD 1.13B 73.7M 2026-06
J&J USD 22.54B 1.21B 2026-03
Moderna USD 17M 54M 2026-06
Neurocrine Biosciences USD 887M 118.9M 2026-06
Pfizer USD 16.19B 19M 2026-06
Prothena USD 5.16M 0 2023-12
PTC Therapeutics USD 219.92M 38.3M 2026-03
Sarepta Therapeutics USD 393.8M 154.11M 2026-06
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12
Vertex Pharmaceuticals USD 2.13B 138.2M 2026-06